Skip to main content
. 2022 Mar 1;42(3):243–252. doi: 10.1007/s40261-022-01122-0

Fig. 1.

Fig. 1

Cumulative proportion of eligible patients with chronic and severe PTSD who received with MDMA-AT over 10 years under three treatment targets. MDMA-AT 3,4-methylenedioxymethamphetamine assisted-therapy, PTSD post-traumatic stress disorder